Early research (Phase 1)WithdrawnNCT05609045
What this trial is testing
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
Who this might be right for
COVID-19 Pandemic
Wuhan Rhegen Biotechnology Co., Ltd.